CO2021014351A2 - Derivados de quinolina y su uso para el tratamiento del cáncer - Google Patents

Derivados de quinolina y su uso para el tratamiento del cáncer

Info

Publication number
CO2021014351A2
CO2021014351A2 CONC2021/0014351A CO2021014351A CO2021014351A2 CO 2021014351 A2 CO2021014351 A2 CO 2021014351A2 CO 2021014351 A CO2021014351 A CO 2021014351A CO 2021014351 A2 CO2021014351 A2 CO 2021014351A2
Authority
CO
Colombia
Prior art keywords
cancer treatment
quinoline derivatives
compounds
quinoline
derivatives
Prior art date
Application number
CONC2021/0014351A
Other languages
English (en)
Inventor
Eamon Comer
Kenneth Duncan
Alexis Cocozaki
John Campbell
Darren Harvey
Michael MUNCHHOF
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CO2021014351A2 publication Critical patent/CO2021014351A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente divulgación proporciona nuevos compuestos, composiciones que comprenden los compuestos y métodos de uso de los mismos.
CONC2021/0014351A 2019-03-28 2021-10-26 Derivados de quinolina y su uso para el tratamiento del cáncer CO2021014351A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825507P 2019-03-28 2019-03-28
US201962952599P 2019-12-23 2019-12-23
PCT/US2020/025160 WO2020198567A1 (en) 2019-03-28 2020-03-27 Quinoline derivatives and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
CO2021014351A2 true CO2021014351A2 (es) 2022-01-17

Family

ID=70334131

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014351A CO2021014351A2 (es) 2019-03-28 2021-10-26 Derivados de quinolina y su uso para el tratamiento del cáncer

Country Status (14)

Country Link
US (1) US20220144812A1 (es)
EP (1) EP3946623A1 (es)
JP (1) JP2022527279A (es)
KR (1) KR20210151849A (es)
CN (1) CN113891749A (es)
AU (1) AU2020244861A1 (es)
BR (1) BR112021019300A2 (es)
CA (1) CA3134826A1 (es)
CL (2) CL2021002501A1 (es)
CO (1) CO2021014351A2 (es)
IL (1) IL286649A (es)
MX (1) MX2021011699A (es)
SG (1) SG11202110591SA (es)
WO (1) WO2020198567A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022138944A1 (ja) * 2020-12-25 2022-06-30 国立研究開発法人国立がん研究センター Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109122D0 (en) * 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
CN101370782A (zh) * 2005-12-12 2009-02-18 阿斯利康(瑞典)有限公司 烷基磺酰胺喹啉
US20090054445A1 (en) * 2006-01-27 2009-02-26 Astrazeneca Ab Amide Substituted Quinolines
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
CN101289460B (zh) * 2008-06-06 2011-09-14 山东大学 有机硼酸类化合物及其作为荧光探针的应用
NZ602099A (en) * 2008-07-10 2014-06-27 Pharma Ip General Inc Ass Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
AU2016245864C1 (en) * 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CA3031525A1 (en) 2016-07-25 2018-02-01 Epizyme, Inc. Crebbp related cancer therapy
EP3515449B1 (en) * 2016-09-26 2023-07-12 Dana-Farber Cancer Institute, Inc. Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
ES2955132T3 (es) * 2016-12-19 2023-11-28 Epizyme Inc Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos

Also Published As

Publication number Publication date
EP3946623A1 (en) 2022-02-09
CA3134826A1 (en) 2020-10-01
JP2022527279A (ja) 2022-06-01
CL2021002501A1 (es) 2022-06-17
MX2021011699A (es) 2022-01-18
CN113891749A (zh) 2022-01-04
KR20210151849A (ko) 2021-12-14
WO2020198567A1 (en) 2020-10-01
BR112021019300A2 (pt) 2021-12-14
SG11202110591SA (en) 2021-10-28
CL2022003206A1 (es) 2023-07-07
IL286649A (en) 2021-10-31
AU2020244861A1 (en) 2021-11-18
WO2020198567A8 (en) 2020-11-19
US20220144812A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CO2020015437A2 (es) Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2017000195A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
ECSP18056196A (es) Derivados de indano
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores